Valvular & structural heart disease
Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure
Main findingResult — go to the resultWeighted hazard ratio 1.04 95% CI 0.59–1.83Authors' conclusion
The antiplatelet strategy following PFO closure did not seem to impact clinical outcomes
Study context
- Population
- Consecutive patients undergoing patent foramen ovale (PFO) percutaneous closure discharged without anticoagulation, 7 centres in France and Canada, 2001–2022AIR-FORCE cohort
- Participants
- 1,532 patients
- Exposure
- Single antiplatelet therapy (SAPT) vs dual antiplatelet therapy (DAPT) at discharge after PFO closure
- SAPTn = 599
- DAPTn = 933reference
- Outcome
- Composite of:
- Death
- Stroke
- TIA
- Peripheral embolism
- MI
- BARC type ≥2 bleeding
- Follow-up
- Up to 5 years
Methodological detailsmulticentre, propensity-score inverse probability weighting, consecutive patients
- Multicentre
- Propensity-score inverse probability weighting
- Consecutive patients
Main finding
As reported in the abstract
Weighted hazard ratio
1.04
95% CI 0.59–1.83
By group
SAPTvs DAPT
weighted HR 1.04 (95% CI 0.59–1.83)
- Total events
- 58
Observational data: associations, not effects.
Original publication
Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure. Eur Heart J Cardiovasc Pharmacother. Published 24 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →